Technical Data
L2024-50
LeukinFeron (LF)
10KU
Molecular Biology Storage: -20°CShipping: Blue Ice
Human LeukinFeron is a combines preparation of natural cytokines involved in cellular reactions elimination of pathogen (antigen). Treatment with LeukinFeron results in a reduced frequency of side effects caused by prospidine therapy. Human LeukinFeron in the combined therapy of Kaposi’s sarcoma leads to a considerable improvement of the initially abnormal levels of immunocompetent and phagocytizing cells. A single dose of Human LeukinFeron is prodced from 1million leukocytes isolated from doner’s blood contains natural IFN-alpha 10,000IU and a complex of cytokines from the first phase of the immune response at their natural ratio, e.g., IL-6, IL-12, TNF-alpha, MIF and LIF.

LF activates expression of HLA-Dr antigens on Human immune effectors and improve immune recognition. LF provides the normalizing action on CD4/CD8 cells interaction and cytokine production by immunocompetent cells that is important for immunoreactivity. LF is applied for the treatment of many viral  diseases, bacterial infections, including sepsis, tuberculosis, chlamidial, mucoplasmic, herpetic infections and oncological diseases.

Source: Leukocytes from donor’s blood.

Contents: 1 vial contains natural IFN-alpha 10,000IU, plus IL-6, IL-12, TNF-alpha, MIF and LIF at native ratios.

Solubility: Very soluble in water and most aqueous buffers.

Stability: Stable at RT. Store desiccated below 0°C. Reconstituted HuLF is best stored refrigerated at 4°C.

Endotoxin: 0.1ng/ug (IEU/ug) of HuLF.
Concentration: As reported
Form: Supplied as a sterile-filtered, white lyophilized powder in 0.1M sodium chloride, HSA.


Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.